Xcout Intel
Archon Biosciences
Archon Biosciences is a biotechnology company based in Seattle, Washington, supported by investors like Madrona Ventures. The company utilizes its proprietary AbC technology platform to develop innovative therapeutics and advance drug pipelines.
Subscribe to see Archon Biosciences’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Archon Biosciences at a glance
Archon Biosciences is a biotech company headquartered in United States. Its most recent funding round, Grant, raised $20M in October 2024. Xcout tracks 4 named people at Archon Biosciences, including David Baker (co-founder).
Archon Biosciences leadership
- David Bakerco-founder
- George UedaCo-Founder
- James LazarovitsBoard Member, Co-Founder
- Jamison WrightBoard Member
Archon Biosciences funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Grant | $20M | 12 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Archon Biosciences competitors
A few of Archon Biosciences's closest competitors — see the full list of competitors and alternatives →
Modulus Therapeutics, Inc. is a research and development business services company located in Washington state, focusing on therapeutic innovations.
Avicenna Biosciences, Inc. is a biotechnology company that uses machine learning-enhanced medicinal chemistry to accelerate drug discovery and optimization.
Adnexus Biotechnologies is a drug discovery and biotechnology company headquartered in Texas that focuses on delivering accessible and affordable therapeutic solutions.
Launched in 2022 and headquartered in Seattle, Washington, Vilya is an AI peptide company co-founded by scientists from the Institute of Protein Design. The company uses artificial intelligence and synthetic biology to design novel macrocycle therapeutics inspired by nature.
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.
AbCellera is a biotechnology company that integrates biology, computation, and engineering to discover and develop antibody-based medicines. The company operates a proprietary technology platform to advance internal and partnered drug programs across therapeutic areas such as endocrinology, immunology, autoimmunity, and oncology.
Get Archon Biosciences's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Archon Biosciences in Xcout Intel
- 4 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access